Empirical research has supported the tripartite model's utility, especially with regard to the two dimensions that separate depression and anxiety (low positive affect and high physiological hyperarousal, respectively), which have proven to be orthogonal. The comorbidity is explained almost exclusively by an increase in negative affect in both conditions, which links anxiety and depression with constructs such as neuroticism. Other models, such as the approach-withdrawal model or the valence-arousal model, rely on affective styles stemming from the interaction of motivation and emotion, as well as on the neural circuits assumed to underlie these constructs. 6 The approach system (positive affect and reward response) and the withdrawal system (avoidance and negative affect) involve overlapping, yet dissociable neural circuits: left prefrontal cortex and the basal ganglia for the approach system, right prefrontal cortex for the withdrawal system, with the amygdala playing a crucial role in both systems. 6 These models propose various permutations among the basic factors as the source of comorbidity, but as a rule, they advance endophenotypes designed to increase the diagnostic validity.
More recently, bipolar vulnerability has also been suggested as a source of comorbidity. The study by Coryell and colleagues 7 in this issue supports the prognostic importance of anxiety symptoms in the long-term outcome of both unipolar and bipolar depression.
Further insights into the sources of comorbidity have come from gene-environment interaction studies. These have shown that genetic risk factors for major depression and generalised anxiety are strongly correlated, but that the majority of the genetic covariance between the two disorders results from factors not shared with neuroticism (which accounted for only about 25% of this correlation). 8 Such results contradict the architecture of the tripartite model, in which negative affect is the intermediate phenotype of comorbid anxiety-depression. In addition, neuroticism-independent genetic factors seem to significantly increase the risk for major depression, generalised anxiety disorder and panic disorder, showing that there is substantial, but not complete, overlap between the genetic factors that influence individual variation in neuroticism and those that increase liability for both depression and anxiety. 7 As epistemic iteration requires building on incremental knowledge, the construct of comorbid depression and anxiety is currently being deliberated not through sophisticated psychological models, but through progress in the biological realms of receptor changes, neuropeptide systems alterations, dysregulation in intracellular signalling, changes in gene sequence or expression, or alteration in brain circuits. 9 How relevant are these advances to the pathophysiology of anxious depression? A brief overview is required.
Serotonin plays an important modulatory role in emotion, motivation and cognition, and its dysfunction contributes to
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Comorbid anxiety and depression: bê te noire or quick fix? many disorders, including mood and anxiety disorders, psychosis and substance misuse. Serotonin transporter knockout rodents have been extensively characterised in well-validated tests for anxiety-and depression-like behaviour. However, depression and anxiety-like symptoms are less robust in these animal models, suggesting that the monoaminergic dysregulation is most likely intermingled with dysregulation in other systems such as the glutamatergic or peptidergic systems, in particular neuropeptide Y (NPY) and vasopressin. 9 The importance of vasopressin, corticotropin-releasing hormone, oxytocin, prolactin, neuropeptide Y and neuropeptide S as neuromodulators of emotionality is becoming increasingly apparent. Differences in these peptides' behaviour in depression v. anxiety models are frequently reported. 9 Thus, specific agonists of the NPY1 receptor are purely anxiolytic, whereas NPY2 antagonists have anxiolytic and antidepressant potential; urocortin 1 has no effect in depressive models, whereas it has anxiogenic properties; oxytocin has been extensively studied for its anxiolytic effect, whereas its antidepressant effect is still unclear. So far, there are no studies addressing neuropeptide changes in comorbid anxious depression, so we cannot make inferences regarding their role in supporting a distinct diagnosis of anxious depression.
One relevant neurotrophin that has been connected to comorbid anxious depression is the brain-derived neurotrophic factor (BDNF). Recent data showed that the BDNF Val66Met allele was significantly more abundant in individuals with comorbid anxious depression than in individuals with pure depression or pure anxiety. Proinflammatory cytokines (interferon-alpha, interleukin-2, interleukin-1-beta, interferongamma) have been implicated in the pathophysiology of mood disorders, through their influence on monoaminergic metabolism and the hypothalamic-pituitary-adrenocortical (HPA) axis, but again, there are no studies addressing their role in anxious depression. This brings us to the most studied system -the HPA axis. Clinical and preclinical studies have reported HPA-axis dysregulation in mood and anxiety disorders, with higher cortisol levels in comorbid anxious depression than in pure major depressive disorder or pure generalised anxiety disorder. The association of HPA axis and the tripartite model of Clark & Watson 5 has shown that morning cortisol was not linked to DSM-IV diagnoses of anxiety disorders or major depressive disorder, but to specific symptoms such as anhedonia, worry and negative affect, thus making an argument for a dimensional diagnostic model.
Although neuroimaging studies pertinent to either depression or anxiety have flooded MEDLINE in the past two decades and transformed the amygdala into a star, a surprisingly small number of studies explored the neural markers of anxiety-depression comorbidity. 10 Anxiety-depression comorbidity has been characterised by more right than left hemispheric anterior activity in people with major depressive disorder, consistent with a key role of the right prefrontal cortex in anxiety disorders. 6 Sustained activation in the dorsal anterior cingulate cortex has been described as a marker of anxiety superimposed on depression, results confirmed by a voxel-based morphometry study indicating that reduced volume of dorsal anterior cingulate cortex is a non-specific effect of comorbid anxiety and depression. Moreover, the connectivity patterns in the default-mode network in late-life depression are modified by the presence of increased anxiety symptoms. 10 The functional neuroimaging experiments have still to move the field forward clinically, to offer sensitive and specific biomarkers of diagnostic and treatment response, but the few results available suggest that comorbid anxious depression leaves a different neural imprint than pure depression or pure anxiety.
To return to the epistemic iteration model, it seems we generate increasingly accurate estimations of the biological features of 'out-in-the-world' anxious depression, but the asymptotic nature of the process does not allow for fast gratification. The overall direction of the most recent biological findings points towards a valid comorbid entity, one that has been for a long time a nosological bête noir owing to its complexity. The current failure to allow the diagnosis of mixed anxiety-depression (subthreshold major depressive disorder plus subthreshold anxiety disorder) has notable treatment consequences: practitioners may not provide optimal pharmacotherapy or psychotherapy (such as simple-to-deliver internet cognitive-behavioural therapy 11 ), or even fail to detect or treat the symptoms as they do not fall in the prescribed DSM category. 12 We expect eventual applications from neuroscience and genetics to revolutionise the diagnosis and treatment of mental disorders. Current efforts, including those listed above, remind us though that we tackle the 'most complexly organized structure in the universe [ . . . ] and the number of possible permutations and combinations of brain activity, in other words the numbers of brain states, exceeds the number of elementary particles in the known universe' . 13 Maybe attempts to achieve DSM validity, especially in contentious areas like comorbid anxious depression, will take more iterations, but some of the dismissive approaches reviewed in the first paragraph of this editorial remind us of a story about the late Francis Crick: 'All this stuff on the brain is interesting, Dr Crick,' a lady asked him during a fund-raiser, 'but can you name any one single discovery in the last two decades that has really important implications?' 'Well, my dear', replied Crick, 'one thing we have now learnt is that the brain is really plastic'.
